Head to head

Cagrilintide vs SLU-PP-332

Metabolic

A comparison decided mostly by evidence: Cagrilintide has been studied in people to a degree the other has not.

Verdict

One has been tested in people; the other has not

If your priority is the compound with the strongest published support, that is Cagrilintide. SLU-PP-332 is not therefore worse — it is less examined, which is a different thing — but the gap is the single most defensible difference on this page, and it is the one most comparisons quietly skip.

What you are actually choosing between

Both are classed here as metabolic compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is fat loss and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — Cagrilintide rates 4/5 for fat loss and SLU-PP-332 rates 4/5. Outside that overlap only Cagrilintide goes further, carrying weight for appetite control; SLU-PP-332's declared goals stop at the overlap.

The evidence

This is the part that decides most of it. Cagrilintide has controlled human trials behind it, without an approval — investigational; standalone long-term data does not exist yet. SLU-PP-332 has animal and cell data only, and no controlled human dosing trials — there are no human trials of any kind. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

Cagrilintide is a subcutaneous injection; SLU-PP-332 is taken by mouth. That is the difference most people actually feel: Cagrilintide means reconstituting a vial and injecting; SLU-PP-332 does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Cagrilintide has a characterized half-life of 7.5 days; SLU-PP-332 does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.

One of these has an end date and the other does not: Cagrilintide runs no fixed cycle, SLU-PP-332 runs 8 weeks. An open-ended compound is a standing commitment, not a course you finish. Cagrilintide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

Cagrilintide

Long-acting amylin analogue, not a GLP-1. Phase 2 randomized human trials dosed 0.3 to 4.5 mg once weekly with 4-week step-ups, and it is in phase 3 combined with semaglutide as CagriSema. It is investigational and NOT approved anywhere as a standalone product. Amylin analogues act on satiety through a different receptor to GLP-1, which is the rationale for the combination, but standalone long-term data does not yet exist.

SLU-PP-332

A synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), not a peptide. It is marketed as an "exercise mimetic" because in mice it increased oxidative metabolism, running endurance and fat oxidation and reduced fat gain on a high-fat diet without changing food intake. That is the entire evidence base: preclinical rodent and cell work from academic labs. There are NO human trials, no human pharmacokinetics, no human safety data and no published human dosing whatsoever — nothing here is derived from a study in people. It is sold as 1 mg oral tablets, so the 500-1000 mcg (0.5-1 mg) daily range shown is simply half a tablet to one tablet: a deliberately narrow, conservative reading of vendor packaging, not a validated dose. Human half-life is unknown, so it is left null rather than guessed. It is swallowed as tablets rather than reconstituted, so the reconstitution fields do not apply. Treat every number on this page as the lowest possible confidence.

Side by side

The numbers

Cagrilintide compared with SLU-PP-332
Attribute	Cagrilintide	SLU-PP-332
Class	Metabolic	Metabolic
Routes	Subcutaneous	Oral
Dose range	300 mcg–4.5 mg (typical 2.4 mg)	500 mcg–1 mg (typical 1 mg)
Frequency	Once a week	Once daily
Half-life	7.5 days	Not characterized
Cycle length	No fixed cycle	8 weeks
Experience	Advanced	Advanced
Evidence	Controlled human trials	Animal / cell data only
Contraindications	Pregnant / nursing Under 18	Pregnant / nursing Under 18
Side effects	Nausea, generally milder than with a GLP-1 at equivalent appetite suppression Constipation Injection site reactions Reduced appetite and early satiety	Unknown in humans — no clinical safety data of any kind exists Stimulant-like restlessness or insomnia reported anecdotally, not in any trial Elevated heart rate reported anecdotally Rodent studies used doses far above anything sold to consumers, so the animal safety record does not translate to human tablets

Turn a typical dose into a mark on the syringe: Cagrilintide

Goals

Where they overlap, and where they do not

Goal	Cagrilintide	SLU-PP-332
fat loss	Cagrilintide: 4/5	SLU-PP-332: 4/5
metabolic health	Cagrilintide: 3/5	SLU-PP-332: 4/5
appetite controlone only	Cagrilintide: 5/5	SLU-PP-332: —
longevityone only	Cagrilintide: —	SLU-PP-332: 2/5
muscle growthone only	Cagrilintide: —	SLU-PP-332: 2/5

They overlap on 2 goals and diverge on 3. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCagrilintideMechanism, protocol, storage, sources.MonographSLU-PP-332Mechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.